jRCT2031210570
进行中（未招募）
不适用
AYD001 Phase III Clinical Trial (AYD001/CT1)
Yoshindo Inc.0 个研究点目标入组 60 人2021年11月1日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Yoshindo Inc.
- 入组人数
- 60
- 主要终点
- -
- 状态
- 进行中（未招募）
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •(1) Patients undergoing hemodialysis for 3 to 5 hours per session, 3 times a week at the time of informed consent.
- •(2) Patients aged 20 to less than 90 years old.
- •(3) Patients providing written informed consent about participation in this clinical study
排除标准
- •(1) Patients within 26 weeks of initiating hemodialysis at the time of informed consent
- •(2) Patients with severe hepatic function impairment
- •(3) Patients with severe heart disease
- •(4) Patients with severe respiratory disorder
结局指标
主要结局
-
Correction of azotemia (BUN, Cre, and UA)
相似试验
进行中（未招募）
3 期
AYD001 Phase III Clinical TrialPatients with chronic renal failure undergoing hemodialysisJPRN-jRCT2031210570Asaoka Kuniharu60
进行中（未招募）
不适用
X01-315-02 / ?A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7R Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma? - Allovectin-7R Immunotherapy for Metastatic Melanoma (A.I.M.M.)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-ITVICAL INCORPORATED375
招募中
3 期
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type IIfocal cortical dysplasia type IIFCDJPRN-jRCT2031230317Kato Mituhiro20
进行中（未招募）
不适用
A phase III study (physician-initiated clinical trial) to evaluate the efficacy and safety of sirolimus for epileptic seizures with focal cortical dysplasia type IIjRCT203123031720
进行中（未招募）
不适用
A PHASE III TRIAL OF ALD-101 ADUVANT THERAPY of UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH INBORN ERRORS OF METABOLISMInborn errors of metabolismMedDRA version: 9.1Level: LLTClassification code 10062018Term: Inborn error of metabolismEUCTR2009-011921-15-NLAldagen, Inc40